These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36476830)

  • 1. Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.
    Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H
    Circ J; 2024 Jan; 88(2):217-225. PubMed ID: 36476830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy.
    Moriyama S; Hieda M; Kisanuki M; Kawano S; Yokoyama T; Fukata M; Kusaba H; Maruyama T; Baba E; Akashi K; Fukuda H
    Open Heart; 2022 Dec; 9(2):. PubMed ID: 36600585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Maitland ML; Bakris GL; Black HR; Chen HX; Durand JB; Elliott WJ; Ivy SP; Leier CV; Lindenfeld J; Liu G; Remick SC; Steingart R; Tang WH;
    J Natl Cancer Inst; 2010 May; 102(9):596-604. PubMed ID: 20351338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors.
    Pucci G; Milan A; Paini A; Salvetti M; Cerasari A; Vaudo G
    Expert Opin Biol Ther; 2019 May; 19(5):433-442. PubMed ID: 30888868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.
    Touyz RM; Herrmann SMS; Herrmann J
    J Am Soc Hypertens; 2018 Jun; 12(6):409-425. PubMed ID: 29703600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine Kinase Inhibitor-Induced Hypertension.
    Agarwal M; Thareja N; Benjamin M; Akhondi A; Mitchell GD
    Curr Oncol Rep; 2018 Jun; 20(8):65. PubMed ID: 29931399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
    Hamnvik OP; Choueiri TK; Turchin A; McKay RR; Goyal L; Davis M; Kaymakcalan MD; Williams JS
    Cancer; 2015 Jan; 121(2):311-9. PubMed ID: 25236375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factor analysis for regorafenib-induced severe hypertension in metastatic colorectal cancer treatment.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2022 Dec; 30(12):10203-10211. PubMed ID: 36217043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
    Groarke JD; Choueiri TK; Slosky D; Cheng S; Moslehi J
    Curr Treat Options Cardiovasc Med; 2014 Sep; 16(9):335. PubMed ID: 25099086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
    Steingart RM; Bakris GL; Chen HX; Chen MH; Force T; Ivy SP; Leier CV; Liu G; Lenihan D; Lindenfeld J; Maitland ML; Remick SC; Tang WH
    Am Heart J; 2012 Feb; 163(2):156-63. PubMed ID: 22305831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
    Touyz RM; Herrmann J
    NPJ Precis Oncol; 2018; 2():13. PubMed ID: 30202791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors.
    Thompson LA; Saseen JJ; O'Bryant CL; Allen RR; Nair KV
    J Oncol Pharm Pract; 2015 Aug; 21(4):258-67. PubMed ID: 24727344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Team-Based Approach to Management of Hypertension Associated with Angiogenesis Inhibitors.
    Patel S; Dushenkov A; Jungsuwadee P; Krishnaswami A; Barac A
    J Cardiovasc Transl Res; 2020 Jun; 13(3):463-477. PubMed ID: 32430701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension in cancer patients treated with anti-angiogenic based regimens.
    Wasserstrum Y; Kornowski R; Raanani P; Leader A; Pasvolsky O; Iakobishvili Z
    Cardiooncology; 2015 Dec; 1(1):6. PubMed ID: 33530150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
    Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
    Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
    Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications.
    Sung HK; Michael IP; Nagy A
    Curr Opin Hematol; 2010 May; 17(3):206-12. PubMed ID: 20216210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.